Vaccin Antirabic Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends
Top Countries — Revenue
Access the full forecast model.
Country-level data · Company profiles · Editable dataset · Analyst consultation included.
Vaccin Antirabic Market Analysis — Presence
Geographical Analysis
Click countries to exploreRegional and Country Analysis
Global Vaccin Antirabic Market Analysis 2026
| Region / Country | 2021 (A) | 2025 (A) | 2033 (P) | CAGR |
|---|---|---|---|---|
| Global | $ 987.07 Million | $ 1427.9 Million | $ 2988.14 Million | 9.67% |
| North America | $ 289.41 Million | $ 407.24 Million | $ 828.31 Million | 9.281% |
| United States | $ 225.33 Million | $ 315.45 Million | $ 637.47 Million | 9.192% |
| Canada | $ 41.79 Million | $ 59.62 Million | $ 124.58 Million | 9.649% |
| Mexico | $ 22.28 Million | $ 32.17 Million | $ 66.27 Million | 9.453% |
| Europe | $ 213.21 Million | $ 299.86 Million | $ 618.54 Million | 9.473% |
| United Kingdom | $ 23.88 Million | $ 34.18 Million | $ 71.75 Million | 9.711% |
| France | $ 24.31 Million | $ 33.28 Million | $ 66.18 Million | 8.972% |
| Germany | $ 34.33 Million | $ 49.78 Million | $ 106.39 Million | 9.96% |
| Italy | $ 13.43 Million | $ 17.69 Million | $ 34.02 Million | 8.516% |
| Russia | $ 26.65 Million | $ 36.28 Million | $ 72.37 Million | 9.014% |
| Spain | $ 15.56 Million | $ 20.99 Million | $ 42.68 Million | 9.276% |
| Sweden | $ 11.09 Million | $ 14.99 Million | $ 29.07 Million | 8.629% |
| Denmark | $ 9.23 Million | $ 12.59 Million | $ 25.36 Million | 9.144% |
| Switzerland | $ 9.17 Million | $ 12.29 Million | $ 24.12 Million | 8.791% |
| Luxembourg | $ 6.61 Million | $ 8.7 Million | $ 17.32 Million | 8.994% |
| Rest of Europe | $ 38.95 Million | $ 59.07 Million | $ 129.28 Million | 10.285% |
| Asia Pacific | $ 353.37 Million | $ 514.04 Million | $ 1129.52 Million | 10.341% |
| China | $ 137.81 Million | $ 202.02 Million | $ 457.45 Million | 10.757% |
| Japan | $ 39.08 Million | $ 54.8 Million | $ 115.89 Million | 9.815% |
| South Korea | $ 18.73 Million | $ 24.67 Million | $ 48.57 Million | 8.834% |
| India | $ 63.25 Million | $ 95.1 Million | $ 216.87 Million | 10.854% |
| Australia | $ 7.53 Million | $ 9.92 Million | $ 19.54 Million | 8.842% |
| Singapore | $ 10.95 Million | $ 14.91 Million | $ 30.5 Million | 9.36% |
| Taiwan | $ 11.66 Million | $ 15.94 Million | $ 32.76 Million | 9.425% |
| South East Asia | $ 53.96 Million | $ 79.52 Million | $ 165.36 Million | 9.583% |
| Rest of APAC | $ 10.39 Million | $ 17.17 Million | $ 42.58 Million | 12.024% |
| South America | $ 55.28 Million | $ 97.1 Million | $ 206.18 Million | 9.87% |
| Brazil | $ 18.79 Million | $ 33.3 Million | $ 71.34 Million | 9.99% |
| Argentina | $ 7.19 Million | $ 12.33 Million | $ 24.95 Million | 9.208% |
| Colombia | $ 3.7 Million | $ 6.6 Million | $ 14.23 Million | 10.071% |
| Peru | $ 3.1 Million | $ 5.24 Million | $ 10.72 Million | 9.353% |
| Chile | $ 2.27 Million | $ 3.79 Million | $ 7.84 Million | 9.514% |
| Rest of South America | $ 20.23 Million | $ 35.83 Million | $ 77.11 Million | 10.055% |
| Middle East | $ 46 Million | $ 66.54 Million | $ 124.31 Million | 8.125% |
| Saudi Arabia | $ 18.68 Million | $ 27.35 Million | $ 50.94 Million | 8.086% |
| Turkey | $ 10.53 Million | $ 14.97 Million | $ 27.6 Million | 7.944% |
| UAE | $ 5.36 Million | $ 7.83 Million | $ 15.04 Million | 8.511% |
| Egypt | $ 5.15 Million | $ 7.59 Million | $ 14.42 Million | 8.36% |
| Qatar | $ 3.88 Million | $ 5.82 Million | $ 10.99 Million | 8.279% |
| Rest of Middle East | $ 2.39 Million | $ 2.99 Million | $ 5.32 Million | 7.45% |
| Africa | $ 29.81 Million | $ 43.12 Million | $ 81.28 Million | 8.245% |
| East Africa | xxxx | xxxx | xxxx | xxxx |
| West Africa | xxxx | xxxx | xxxx | xxxx |
| North Africa | xxxx | xxxx | xxxx | xxxx |
| South Africa | $ 12.94 Million | $ 18.54 Million | $ 34.54 Million | 8.087% |
A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.
Unlock full regional dataset →Segmentation Analysis
Type breakdown · Illustrative 2025 shares shown free · Full-period forecast in paid report.
Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.
To learn more about market share and segmentation, request the free sample pages.
Competitor Analysis
The pharmaceutical and healthcare industry is highly competitive, with players expanding through product launches, M&A, partnerships, and regulatory approvals. The Vaccin Antirabic Market Analysis market report covers financials, market share, SWOTs, and responses to Tariffs, while providing global, regional, and country-level forecasts supported by value chain, patent analysis, and a competitive matrix serving as a key resource for stakeholders and investors.
| Top Companies (In no particular order) | 2022 (A) | 2023 (A) | 2024 (A) | 2025 (A) |
|---|---|---|---|---|
| Company 1 | ••• | ••• | ••• | ••• |
| Company 2 | ••• | ••• | ••• | ••• |
| Company 3 | ••• | ••• | ••• | ••• |
| Company 4 | ••• | ••• | ••• | ••• |
| Company 5 | ••• | ••• | ••• | ••• |
We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.
Request company profile for validation →Report Scope & Analysis
Executive Summary of Vaccin Antirabic Market
The global market for anti-rabies vaccines is on a significant upward trajectory, projected to grow from $987.07 million in 2021 to $2,988.14 million by 2033, demonstrating a compound annual growth rate (CAGR) of 9.67%. This expansion is primarily propelled by the persistent high incidence of rabies, particularly in developing regions, and concerted efforts by global health organizations to eradicate the disease. The Asia-Pacific region stands out as the largest and most rapidly growing market, a direct consequence of its large population, high number of stray animals, and increasing government-led vaccination drives. Key market drivers include rising awareness about zoonotic diseases, growth in the pet population, and advancements in vaccine technology, such as the shift towards safer and more effective cell-culture vaccines. Despite this positive outlook, the market faces restraints, including the high cost of post-exposure prophylaxis (PEP) and logistical challenges in maintaining the vaccine cold chain in remote areas.
Key strategic insights from our comprehensive analysis reveal:
- The Asia-Pacific region is the epicenter of market growth, representing the largest share and highest CAGR, driven by immense public health needs in countries like India and China.
- A clear market trend is the technological shift from traditional nerve tissue vaccines to modern, safer, and more efficacious cell-culture and recombinant vaccines, creating opportunities for innovation-focused manufacturers.
- The high cost of treatment and logistical complexities in vaccine distribution remain significant barriers, highlighting the need for cost-effective solutions and improved healthcare infrastructure, especially in low-income nations.
Strategic Recommendations for Manufacturers
Manufacturers should prioritize investment in R&D to develop more affordable, heat-stable, and single-dose rabies vaccines to address the critical needs of high-burden, low-income markets. Expanding manufacturing capacity in the Asia-Pacific region can help meet the surging demand and reduce logistical costs. Forming strategic public-private partnerships with governments and NGOs to support mass vaccination campaigns and awareness programs can secure long-term contracts and enhance brand reputation. Furthermore, focusing on the growing veterinary vaccine segment by offering tailored products for companion animals and livestock presents a significant, parallel revenue stream.
The pharmaceutical and healthcare industry is growing rapidly, driven by aging populations, chronic disease prevalence, and rising healthcare spending. Innovations in precision medicine, gene therapy, and digital health are improving outcomes, though challenges include high R&D costs, strict regulations, and pricing pressures. Growth opportunities lie in emerging markets with expanding healthcare infrastructure, while key trends such as AI-driven personalized medicine, telehealth, and sustainable pharma solutions are reshaping the industry.
Analyst Conclusion
Industry Categorization and Context
The Vaccin Antirabic market operates within the broader Pharmaceutical and Healthcare Industry, specifically under Infectious Disease Prevention and Veterinary Medicine. It addresses the critical need for preventing rabies, a nearly 100% fatal viral disease, serving both pre-exposure prophylaxis (PrEP) for at-risk populations and post-exposure prophylaxis (PEP) for individuals potentially exposed to the virus.
Historical Performance and Current Status
Historical Growth: The global Vaccin Antirabic market has demonstrated significant growth, expanding from $987.07 million in 2021 to an estimated $1574.66 million in 2026. This growth is mirrored in key regions such as Asia Pacific, which increased from $353.37 Million in 2021 to $567.23 Million in 2026.
Current Market Leader: Asia-Pacific currently holds the largest share, accounting for approximately 36.02% of the global market, driven by its high disease burden and significant public health initiatives.
Leading Technology & Products: Modern cell-culture vaccines (CCVs), including human diploid cell vaccines (HDCV) and purified chick embryo cell vaccines (PCECV, are the leading technology, becoming the standard of care due to their superior safety and efficacy compared to older nerve tissue vaccines.
Market Projections and Future Outlook
Overall Projection: The global Vaccin Antirabic market is projected to reach $2,988.14 million by 2033, growing at a compound annual growth rate (CAGR) of 9.67%.
Fastest-Growing Region: Asia Pacific is poised for the fastest growth, demonstrating a CAGR of 10.341%, propelled by surging demand and large-scale government initiatives in countries like India and China.
Primary Growth Driver: The persistent high incidence of rabies, particularly in developing regions, coupled with concerted efforts by global health organizations, rising awareness about zoonotic diseases, and advancements in vaccine technology towards safer cell-culture vaccines, will primarily drive this future growth.
Supriya is a Team Lead at Cognitive Market Research & Consulting, leading research initiatives and strategic intelligence projects across the Healthcare, Pharmaceuticals, and Medical Devices & Consumables sectors. With more than two years of experience in market research and data analysis, she plays a key role in helping organizations navigate complex healthcare ecosystems, identify emerging opportunities, and make informed business decisions through data-driven insights and market intelligence.
Combining expertise in both primary and secondary research methodologies with a strong academic foundation in Marketing and Finance, Supriya oversees the execution of market assessments, competitive intelligence studies, forecasting models, stakeholder interviews, trend analysis, and custom consulting engagements. She collaborates with healthcare providers, pharmaceutical manufacturers, medical device companies, industry experts, and other key stakeholders to gather firsthand market perspectives while validating findings through extensive research. Her ability to interpret clinical, commercial, and market data enables clients to better understand industry developments, regulatory influences, innovation trends, and competitive dynamics.
In her leadership role, she manages end-to-end research projects and guides cross-functional teams in delivering high-quality market reports, consulting solutions, and strategic studies. Her expertise in market estimation, forecasting, and analytical modeling helps organizations evaluate market potential, assess growth opportunities, strengthen competitive positioning, and support strategic planning initiatives. By transforming complex healthcare and life sciences data into actionable business intelligence, she enables clients to make confident decisions in rapidly evolving market environments.
Driven by a passion for healthcare innovation and continuous professional development, Supriya remains committed to staying ahead of industry trends, technological advancements, and changing market conditions. Her leadership, analytical mindset, and dedication to research excellence help organizations mitigate risks, capitalize on emerging opportunities, and achieve sustainable growth across the global healthcare and life sciences landscape.
Frequently Asked Questions
★ Reviews
Rate this report
Vaccin Antirabic Market Analysis — Table of Contents
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
| Type | Gopher Kidney Cell Vaccine, Freeze Dried Vero Cell Vaccine, Common Vero Cell Vaccines, Human Diploid Vaccine |
|---|---|
| Application | Pre exposure Prophylaxis, After Exposure Prophylaxis, Additional Doses |
| List of Competitors | Not Disclosed! Request To Preview the List |
Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))
- 1.1 Top Competitors Analysis
- 1.1.1 Global Vaccin Antirabic Market Analysis by Key Players
- 1.1.2 Segment Market Analysis by Key Players
- 1.1.3 Top Players Ranking 2024
- 1.1.4 New Product Launch Analysis
- 1.1.5 Industry Mergers and Acquisition Analysis
- 1.2 Company Profile (Data Subject to Availability) Sample Format
- 1.1 Top Competitors Analysis
Chapter 2. Global Vaccin Antirabic Market Analysis
- 2.1 Global Vaccin Antirabic Market Analysis
- 2.2 Global Vaccin Antirabic Market Analysis by Region
- 2.3 Global Vaccin Antirabic Market Analysis by Type
- 2.4 Global Vaccin Antirabic Market Analysis by Application
- 2.5 Global Vaccin Antirabic Market Analysis by Key Players
Chapter 3. North America Vaccin Antirabic Market Analysis
- 3.1 North America Vaccin Antirabic Market Analysis
- 3.2 North America Vaccin Antirabic Market Analysis by Country
- 3.3 North America Vaccin Antirabic Market Analysis by Type
- 3.4 North America Vaccin Antirabic Market Analysis by Application
- 3.5 North America Vaccin Antirabic Market Analysis by Key Players
Chapter 4. Europe Vaccin Antirabic Market Analysis
- 4.1 Europe Vaccin Antirabic Market Analysis
- 4.2 Europe Vaccin Antirabic Market Analysis by Country
- 4.3 Europe Vaccin Antirabic Market Analysis by Type
- 4.4 Europe Vaccin Antirabic Market Analysis by Application
- 4.5 Europe Vaccin Antirabic Market Analysis by Key Players
Chapter 5. Asia Pacific Vaccin Antirabic Market Analysis
- 5.1 Asia Pacific Vaccin Antirabic Market Analysis
- 5.2 Asia Pacific Vaccin Antirabic Market Analysis by Country
- 5.3 Asia Pacific Vaccin Antirabic Market Analysis by Type
- 5.4 Asia Pacific Vaccin Antirabic Market Analysis by Application
- 5.5 Asia Pacific Vaccin Antirabic Market Analysis by Key Players
Chapter 6. South America Vaccin Antirabic Market Analysis
- 6.1 South America Vaccin Antirabic Market Analysis
- 6.2 South America Vaccin Antirabic Market Analysis by Country
- 6.3 South America Vaccin Antirabic Market Analysis by Type
- 6.4 South America Vaccin Antirabic Market Analysis by Application
- 6.5 South America Vaccin Antirabic Market Analysis by Key Players
Chapter 7. Middle East Vaccin Antirabic Market Analysis
- 7.1 Middle East Vaccin Antirabic Market Analysis
- 7.2 Middle East Vaccin Antirabic Market Analysis by Country
- 7.3 Middle East Vaccin Antirabic Market Analysis by Type
- 7.4 Middle East Vaccin Antirabic Market Analysis by Application
- 7.5 Middle East Vaccin Antirabic Market Analysis by Key Players
Chapter 8. Africa Vaccin Antirabic Market Analysis
- 8.1 Africa Vaccin Antirabic Market Analysis
- 8.2 Africa Vaccin Antirabic Market Analysis by Country
- 8.3 Africa Vaccin Antirabic Market Analysis by Type
- 8.4 Africa Vaccin Antirabic Market Analysis by Application
- 8.5 Africa Vaccin Antirabic Market Analysis by Key Players
Chapter 9. Type Analysis
- 9.1 Gopher Kidney Cell Vaccine
- 9.1.1 Global Gopher Kidney Cell Vaccine Market
- 9.1.2 Global Gopher Kidney Cell Vaccine Market by Region
- 9.2 Freeze Dried Vero Cell Vaccine
- 9.2.1 Global Freeze Dried Vero Cell Vaccine Market
- 9.2.2 Global Freeze Dried Vero Cell Vaccine Market by Region
- 9.3 Common Vero Cell Vaccines
- 9.3.1 Global Common Vero Cell Vaccines Market
- 9.3.2 Global Common Vero Cell Vaccines Market by Region
- 9.4 Human Diploid Vaccine
- 9.4.1 Global Human Diploid Vaccine Market
- 9.4.2 Global Human Diploid Vaccine Market by Region
- 9.1 Gopher Kidney Cell Vaccine
Chapter 10. Application Analysis
- 10.1 Pre exposure Prophylaxis
- 10.1.1 Global Pre exposure Prophylaxis Market
- 10.1.2 Global Pre exposure Prophylaxis Market by Region
- 10.2 After Exposure Prophylaxis
- 10.2.1 Global After Exposure Prophylaxis Market
- 10.2.2 Global After Exposure Prophylaxis Market by Region
- 10.3 Additional Doses
- 10.3.1 Global Additional Doses Market
- 10.3.2 Global Additional Doses Market by Region
- 10.1 Pre exposure Prophylaxis
Chapter 11. Qualitative Analysis (Subject to Data Availability)
- 11.1 Market Drivers
- 11.2 Market Restraints
- 11.3 Market Trends
- 11.4 Market Opportunity
- 11.5 Technological Road Map (Subject to Data Availability)
- 11.6 Product Life Cycle (Subject to Data Availability)
- 11.7 Customer and Buyer Behavior Analysis
- 11.7.1 Digital Engagement, Customer Experience & Relationship Analysis
- 11.7.2 Customer Buying Behavior & Purchase Decision Analysis
- 11.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
- 11.7.4 Pricing, Affordability & Value Perception Analysis
- 11.7.5 Customer Segmentation & Demand Pattern Analysis
- 11.8 PESTEL Analysis
- 11.8.1 Political Factors
- 11.8.2 Economic Factors
- 11.8.3 Social Factors
- 11.8.4 Technological Factors
- 11.8.5 Legal Factors
- 11.8.6 Environmental Factors
- 11.9 Industrial Chain Analysis (Subject to Data Availability)
- 11.9.1 Industry Chain Analysis
- 11.9.2 Manufacturing Cost Analysis
- 11.9.3 Supply Side Analysis
- 11.9.3.1 Raw Material Analysis
- 11.9.3.2 Raw Material Procurement Analysis
- 11.9.3.3 Raw Material Price Trend Analysis
- 11.10 Porter’s Five Forces Analysis
- 11.10.1 Bargaining Power of Suppliers
- 11.10.2 Bargaining Power of Buyers
- 11.10.3 Threat of New Entrants
- 11.10.4 Threat of Substitutes
- 11.10.5 Degree of Competition
- 11.11 Patent Analysis (Subject to Data Availability)
- 11.12 ESG Analysis
- 11.13 Geopolitical Outlook
- 11.13.1 Global Power Realignment & Strategic Alliances
- 11.13.2 Geopolitical Risk Landscape & Conflict Hotspots
- 11.13.3 International Trade Relations & Market Access Environment
- 11.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
- 11.13.5 Supply Chain Resilience, Localization & Resource Nationalism
- 11.13.6 Technology Sovereignty & Digital Geopolitics
- 11.13.7 Strategic Implications for Investment, Growth & Market Entry
- 11.14 AI & Market Transformation
- 11.14.1 Competitive Landscape Disruption & Strategic Shifts
- 11.14.2 AI-Driven Transformation of Industry Value Chain
- 11.14.3 Evolution of Business Models & Revenue Streams
- 11.14.4 AI-Driven Product, Service & Innovation Transformation
- 11.14.5 Customer Behavior, AI Adoption & Future Market Evolution
Chapter 12. TOP 10 Country Analysis
- 12.1 Country 1
- 12.2 Country 2
- 12.3 Country 3
- 12.4 Country 4
- 12.5 Country 5
- 12.6 Country 6
- 12.7 Country 7
- 12.8 Country 8
- 12.9 Country 9
- 12.10 Country 10
Chapter 13. Research Findings
- 13.1 Key Takeaways
- 13.2 Analyst Point of View
- 13.3 Assumptions and Acronyms
Chapter 14. Research Methodology and Sources
- 14.1 Primary Data Collection
- 14.1.1 Steps for Primary Data Collection
- 14.1.1.1 Identification of KOL
- 14.1.2 Backward Integration
- 14.1.3 Forward Integration
- 14.1.4 How Primary Research Help Us
- 14.1.5 Modes of Primary Research
- 14.1.1 Steps for Primary Data Collection
- 14.2 Secondary Research
- 14.2.1 How Secondary Research Help Us
- 14.2.2 Sources of Secondary Research
- 14.3 Data Validation
- 14.3.1 Data Triangulation
- 14.4 Data Representation
- 14.1 Primary Data Collection
Athenaeum AI Dashboard
Our Proprietary Methodology
Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Vaccin Antirabic Market Analysis Market analysis.
Primary Intelligence Gathering
Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.
Secondary Data Triangulation
Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.
Expert Validation Protocol
Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.
Athenaeum AI Processing
Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.
Editorial & QA Review
Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.
Data Assurance Metrics
Analytical Coverage
To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.
Sources from the Pharma and Healthcare Industry
The Three Pillars of End-to-End Market Research Services
We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Vaccin Antirabic Market Analysis market.
Market Survey
Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the vaccin antirabic market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.
- Buyer intent & sentiment analysis
- Purchase cycle mapping
- Price sensitivity research
- Channel preference profiling
- Competitive perception study
Customized Market Data & Reports
Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.
- Ready syndicate report
- Custom data scope & segmentation
- Excel quantitative models
- Board-ready PPT with key findings
- Secure cloud portal access
Strategic Consultation
Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.
- Dedicated analyst assigned to you
- Live walkthrough of findings
- Strategic Q&A sessions
- Go-to-market recommendations
- NDA-protected engagement
Customize This Report
Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.
